R&D Strategies at Pharmaceutical Companies 2020
Language:
Japanese
Product Code No:
C61124200
Issued In:
2020/03
#of Pages:
275
Publication Cycle:
Format:
PDF
Geographic Coverage:
Japan
Industry:
Coverage: (Product/service)
R&D Strategies at Pharmaceutical Companies
Research Target:
Pharmaceutical Companies
Research Content:
I Overview
1. R&D Strategies at Pharmaceutical Companies
2. CRO Market Status
3. SMO Market Status
II R&D Strategies at Leading Pharmaceutical Enterprises
1. Astellas Pharma Inc.
2. AstraZeneca K.K.
3. Eisai Co., Ltd.
4. MSD K.K. a subsidiary of Merck & Co., Inc.,
5. Otsuka Holdings Co., Ltd.
6. ONO PHARMACEUTICAL CO., LTD.
7. Kyowa Hakko Kirin Co., Ltd.
8. GlaxoSmithKline K.K.
9. Sanofi K.K.
10. SHIONOGI & CO., LTD.
11. DAIICHI SANKYO COMPANY, LIMITED
12. Sumitomo Dainippon Pharma Co., Ltd.
13. Takeda Pharmaceutical Company Limited.
14. Mitsubishi Tanabe Pharma Corporation
15. CHUGAI PHARMACEUTICAL CO., LTD.
16. Eli Lilly Japan K.K.
17. Boehringer Ingelheim Japan, Inc.
18. Novartis Pharma K.K.
19. Bayer Yakuhin, Ltd.
20. Pfizer Japn, Inc.
III Strategies of CRO/SMO Enterprises
1. EPS Holdings, Inc.
2. A2 Healthcare Corp.
3. M3, Inc.）
4. CMIC HOLDINGS Co., Ltd..
5. Micron Inc.
• Leading CRO Enterprises: 30 enterprises,
• Leading SMO Enterprises: 28 enterprises